Destruxin B2 (compound 5) is a natural depsipeptide that can be inhibits hepatitis B surface antigen (HBsAg) secretion in Hep3B cells with an IC50 1.30 μM.

BA-AZT1 is the inhibitor for HBV polymerase and sodium taurocholate cotransporting polypeptide (NTCP). BA-AZT1 inhibits the secretion of viral capsid protein HBsAg and HBeAg with IC50 of 0.65 µM and 13.42 µM, inhibits the HBV DNA replication with an IC50 of 0.70 µM.

ALG-000184, a prodrug of the potent Hhepatitis B virus (HBV) capsid assembly modulator ALG-001075, has the potential for the research of HBV infection research.

AIC263282 is a potent Hepatitis B Virus (HBV) capsid assembly modulator with an EC50 of 3.8 nM. AIC263282 shows an IC50 of 61 nM for hERG. AIC263282 exhibits activity against viral replication and hepatitis B surface antigen (HBsAG) on primary human hepatocytes.

Racemomycin C has broad spectrum antibacterial activity and antifungal effect, and it can inhibit PR-8 of influenza virus in tissue culture.

Oudemansin A is an antibiotic. Oudemansin A acts on fungi to inhibit protein, RNA and DNA synthesis.

Aurachin C is an isoprenoid quinoline alkaloid with antiplasmodial, antifungal and antibacterial effects. Aurachin C is a selective terminal oxidases inhibitor.

Aklavin is an antibiotic that shows activity against various bacteriophages, Gram-positive bacteria, and some fungi and viruses.

MDL-860 is a broad-spectrum antipicornavirus compound that has low cytotoxicity toward human cells. MDL-860 can be used for the research of virus infection.

HR-568 exhibits broad-spectrum anti-enterovirus activity. HR-568 inhibits enterovirus species EV-A71, E30 and CVA24 in cell MRC-5 with EC50 of 1.53 μM, 0.4 μM and 1.22 μM. HR-568 targets hydrophobic canyon pocket on the enterovirus capsid protein, and inhibits the virus replication.

DC07090 is a potent, reversible and competitive non-peptidyl human enterovirus 71 3C protease inhibitor with an IC50 and a Ki value for 21.72 μM and 23.29 μM. DC07090 could also inhibit coxsackievirus A16 (CVA16) replication with an EC50 value of 27.76 μM.

ε-Rhodomycinone is a bacterial metabolite found in S. griseoruber. It is a precursor to Rhodomycin D, which is an intermediate in the bioconversion of ε-rhodomycinone to Daunorubicin and Doxorubicin.

VPC162134 is an antibacterial agent, that inhibits H. pylori, C. jejuni, MRSA and S. epidermidis with MIC of 2.9, 17.5, 93.3 and 93.3 μM. VPC162134 is an inhibitor for pyruvate ferredoxin oxidoreductase (PFOR).

Vancomycin prodrug (compound 13c) is a Vancomycin prodrug. Vancomycin prodrug shows antibacterial effect with MICs of 0.78 μM, 0.78 μM, 1.56 μM for S. aureus 330041, MRSA USA 300 and MRSA 3390, respectively. Vancomycin prodrug has the ability to quickly bind to Cys-34 residue of plasma. Vancomycin prodrug exhibits a good therapeutic effect on MRSA USA300 infected mice similar to Vancomycin. Vancomycin prodrug, an albumin-binding acid-sensitive prodrug, effectively reduces Vancomycin’s nephrotoxicity while maintaining its efficacy for Gram-positive bacterial infections.

Thiocillin is a thiopeptide class of RiPPs and anti-bacterial agent. Thiocillin targets the bacterial 50S ribosome. Thiocillin exhibits potent antibacterial activity against a number of agent resistant pathogens.

Tenonitrozole exhibits antibacterial activity through inhibition of pyruvate-ferredoxin oxidoreductase (PFOR). Tenonitrozole inhibits H. pylori and C. jejuni with MICs of 0.7 μM and 5.9 μM.

Tembetarine chloride is a alkaloid that can be isolated from Tinospora cordifolia that exhibits antibacterial activity. Tembetarine chloride exhibits weak cytotoxicity against mouse fibroblasts (L929) and human embryonic kidney cells (HEK293) with IC50 of 1245.33 μg/mL and 1642.81 μg/mL, respectively.

SCUT1-2 is a bifunctional antibacterial agent with good oral bioavailability in mice (F=56.8%). SCUT1-2 can kill the vegetative cells of C. difficile with a MIC of 0.06-0.50 μg/mL, and inhibit spore germination in vitro. SCUT1-2 could alleviate the symptoms of weight loss and diarrhea in mice caused by C. difficile infection (CDI) and prevent recurrent CDI.

Sch725674 is a macrolide compound with antimicrobial activity against brewer's yeast and Candida albicans, with MICs of 8 and 32 μg/ml.

Saquayamycin C has antimicrobial effect, but it has weaker effect against Gram-negative bacteria. Saquayamycin C has inhibitory effect on leukemia P388 cells and Adriamycin-resistant P388 cells.

Saquayamycin B1 has antimicrobial effect, but it has weaker effect against Gram-negative bacteria. Saquayamycin B1 has inhibitory effect on leukemia P388 cells and Adriamycin-resistant P388 cells.

Saquayamycin A has antimicrobial effect, but it has weaker effect against Gram-negative bacteria. Saquayamycin A has inhibitory effect on leukemia P388 cells and Adriamycin-resistant P388 cells.

Saframycin D has the effect of anti-Gram-positive bacteria. Saframycin D also has weak activity against mycobacteria.

Safracin A has anti-Gram-positive bacteria, Gram-negative bacteria and anti-tumor effect.

Ro 14-1761 is a third-generation cephalosporin with antibacterial activity.

RCB18350 is an antituberculosis agent that belongs to the class of isoxazole derivatives. RCB18350 has bacteriostatic activity and inhibits the growth of Mycobacterium tuberculosis with an MIC of 1.25 μg/mL. RCB18350 is effective against multidrug-resistant Mycobacterium tuberculosis (MDR-TB) clinical isolates, slow-growing mycobacteria such as Mycobacterium bovis BCG and Mycobacterium avium.

Pristinamycin IB (Ostreogrycin B2) is an ester peptide antibiotic with anti-Gram-positive bacteria effects.

PreQ1-biotin is a biotin conjugated preQ1 substrate. PreQ1-biotin is used for RNA-TAG (transglycosylation at guanosine) and DNA-TAG. PreQ1-biotin can be used for affinity tagging and pull-down of specific RNAs that have been modified selectively by E. coli tRNA guanine transglycosylase (TGT).

PPO-allene is a covalent botulinum neurotoxin (BoNT) light chain inhibitor (IC50: 20.9 μM). PPO-allene (0.3 mg/kg, i.v.) demonstrates an in vivo half-life of approximately 1.5 h in mice.

Polymyxin D2 is an antibiotic discovered from Bacillus polymyxa, exhibiting antibacterial activity. Its core structure consists of a cyclic heptapeptide moiety and a tripeptide side chain with a fatty acyl residue. Polymyxin D2 can be used in anti-infective research.